Takeda’s blood cancer drug fails to achieve Phase III endpoint
Pevonedistat plus azacitidine did not meet primary endpoint of EFS
Read More
Tag: azacitidine
BMS bags US approval for Onureg
The oral therapy can be used as continued treatment for adults in first remission with acute myeloid leukaemia (AML)
Read More
Venclexta/Venclyxto combo extends myeloid leukaemia survival
Roche also reported that safety for Venclexta/Venclyxto with azacitidine appeared consistent with the known safety profile of these medicines.
Read More
NICE sticks with decision to reject Celgene’s Vidaza
Cost regulators are sticking with a decision to bar some patients with acute myeloid leukaemia from routine NHS access to Celgene’s Vidaza.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
